Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + MEDI-575 + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|MEDI-575||MEDI575|MEDI 575|Tovetumab||PDGFRA Antibody 2||MEDI-575 is a human monoclonal antibody that selectively targets PDGFRA, which has potential antitumor activity (PMID: 30685114).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Carboplatin + MEDI-575 + Paclitaxel||Phase Ib/II||Actionable||In a Phase Ib/II trial, MEDI-575, Paraplatin (carboplatin), and Taxol (paclitaxel) combination treatment resulted in increased toxicity, and did not confer benefit over Paraplatin (carboplatin) plus Taxol (paclitaxel) in non-small cell lung carcinoma (NSCLC) patients (n=99), with a progression-free survival of 4.6 months vs. 5.5 months (HR=2.20, p=0.03), an overall response rate of 31.7% vs. 22.5% (p=0.49), and a median overall survival of 10 months vs. 11.8 months (HR=1.31) (PMID: 30685114).||30685114|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|